Alpelisib and fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the French early access program (Jan, 10.1038/s41388-022-02585-3, 2023)

被引：0
|
作者：
Bello Roufai, D.
Goncalves, A.
de la Motte Rouge, T.
Akla, S.
Blonz, C.
Grenier, J.
Gligorov, J.
Saghatchian, M.
Bailleux, C.
Simon, H.
Desmoulins, I.
Tharin, Z.
Renaud, E.
Bertho, M.
Benderra, M-a
Delaloge, S.
Robert, L.
Cottu, P.
Pierga, J. Y.
Loirat, D.
Bertucci, A.
Renouf, B.
Bidard, F. C.
Lerebours, F.
机构：
[1] Institut Curie,Department of Medical Oncology
[2] Institut Paoli Calmettes,Aix
[3] CRCM,Marseille Univ, CNRS, INSERM, Department of Medical Oncology
[4] Centre Eugène Marquis,Department of Medical Oncology
[5] Gustave Roussy,Department of Cancer Medicine
[6] Institut de Cancérologie de l’Ouest,Department of Medical Oncology
[7] Institut du Cancer d’Avignon,Department of Medical Oncology
[8] Hôpital Tenon,Department of Medical Oncology
[9] AP-HP,Breast Cancer Unit
[10] American Hospital of Paris,Department of Medical Oncology
[11] Centre Antoine Lacassagne,Department of Medical Oncology
[12] University Hospital of Brest,Department of Medical Oncology
[13] Centre Georges-François Leclerc,INSERM U938, Institut Universitaire de Cancérologie
[14] UVSQ,undefined
[15] Paris-Saclay University,undefined
[16] Paris Cité University,undefined
[17] AP-HP Sorbonne Université,undefined
来源：
ONCOGENE | 2023年 / 42卷 / 17期
关键词：
D O I：
10.1038/s41388-023-02615-8
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
引用
收藏
页码：1417 / 1417
页数：1
相关论文
共 50 条
  • [1] Alpelisib and fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the French early access program
    Roufai, D. Bello
    Goncalves, A.
    Rouge, T. De La Motte
    Akla, S.
    Blonz, C.
    Grenier, J.
    Gligorov, J.
    Saghatchian, M.
    Bailleux, C.
    Simon, H.
    Desmoulins, I
    Tharin, Z.
    Renaud, E.
    Bertho, M.
    Benderra, M-A
    Delaloge, S.
    Robert, L.
    Cottu, P.
    Pierga, J. Y.
    Loirat, D.
    Bertucci, A.
    Renouf, B.
    Bidard, F. C.
    Lerebours, F.
    [J]. ONCOGENE, 2023, 42 (23) : 1951 - 1956
  • [2] Alpelisib and fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the French early access program
    D. Bello Roufai
    A. Gonçalves
    T. De La Motte Rouge
    S. Akla
    C. Blonz
    J. Grenier
    J. Gligorov
    M. Saghatchian
    C. Bailleux
    H. Simon
    I. Desmoulins
    Z. Tharin
    E. Renaud
    M. Bertho
    M-A Benderra
    S. Delaloge
    L. Robert
    P. Cottu
    J. Y. Pierga
    D. Loirat
    A. Bertucci
    B. Renouf
    F. C. Bidard
    F. Lerebours
    [J]. Oncogene, 2023, 42 : 1951 - 1956
  • [3] Correction: Alpelisib and fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the French early access program
    D. Bello Roufai
    A. Gonçalves
    T. De La Motte Rouge
    S. Akla
    C. Blonz
    J. Grenier
    J. Gligorov
    M. Saghatchian
    C. Bailleux
    H. Simon
    I. Desmoulins
    Z. Tharin
    E. Renaud
    M. Bertho
    M-A Benderra
    S. Delaloge
    L. Robert
    P. Cottu
    J. Y. Pierga
    D. Loirat
    A. Bertucci
    B. Renouf
    F. C. Bidard
    F. Lerebours
    [J]. Oncogene, 2023, 42 : 1417 - 1417
  • [4] Alpelisib for the treatment of PIK3CA-mutated, hormone receptor-positive, HER2-negative metastatic breast cancer
    Leenhardt, Fanny
    Alexandre, Marie
    Jacot, William
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2021, 22 (06) : 667 - 675
  • [5] Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer
    Andre, Fabrice
    Ciruelos, Eva
    Rubovszky, Gabor
    Campone, Mario
    Loibl, Sibylle
    Rugo, Hope S.
    Iwata, Hiroji
    Conte, Pierfranco
    Mayer, Ingrid A.
    Kaufman, Bella
    Yamashita, Toshinari
    Lu, Yen-Shen
    Inoue, Kenichi
    Takahashi, Masato
    Papai, Zsuzsanna
    Longin, Anne-Sophie
    Mills, David
    Wilke, Celine
    Hirawat, Samit
    Juric, Dejan
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (20): : 1929 - 1940
  • [6] FDA Approval Summary: Alpelisib Plus Fulvestrant for Patients with HR-positive, HER2-negative, PIK3CA-mutated, Advanced or Metastatic Breast Cancer
    Narayan, Preeti
    Prowell, Tatiana M.
    Gao, Jennifer J.
    Fernandes, Laura L.
    Li, Emily
    Jiang, Xiling
    Qiu, Junshan
    Fan, Jianghong
    Song, Pengfei
    Yu, Jingyu
    Zhang, Xinyuan
    King-Kallimanis, Bellinda L.
    Chen, Wei
    Ricks, Tiffany K.
    Gong, Yutao
    Wang, Xing
    Windsor, Katherine
    Rhieu, Steve Y.
    Geiser, Gerlie
    Banerjee, Anamitro
    Chen, Xiaohong
    Turcu, Francisca Reyes
    Chatterjee, Deb K.
    Pathak, Anand
    Seidman, Jeffrey
    Ghosh, Soma
    Philip, Reena
    Goldberg, Kirsten B.
    Kluetz, Paul G.
    Tang, Shenghui
    Amiri-Kordestani, Laleh
    Theoret, Marc R.
    Pazdur, Richard
    Beaver, Julia A.
    [J]. CLINICAL CANCER RESEARCH, 2021, 27 (07) : 1842 - 1849
  • [7] Alpelisib and fulvestrant efficacy in HR-positive HER2-negative PIK3CA-mutant advanced breast cancer: Data from the French early access program.
    Bello, Diana
    Bertucci, Alexandre
    Rouge, Thibault De la Motte
    Blonz, Cyriac
    Akla, Sarra
    Grenier, Julien
    Bailleux, Caroline
    Benderra, Marc Antoine
    Simon, Helene
    Desmoulins, Isabelle
    Tharin, Zoe
    Renaud, Emmanuelle
    Delaloge, Suzette
    Bertho, Marion
    Cottu, Paul H.
    Goncalves, Anthony
    Bidard, Francois-Clement
    Lerebours, Florence
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [8] A pharmacokinetic evaluation of alpelisib for the treatment of HR+, HER2-negative, PIK3CA-mutated advanced or metastatic breast cancer
    Bertho, Marion
    Patsouris, Anne
    Augereau, Paule
    Robert, Marie
    Frenel, Jean-Sebastien
    Blonz, Cyriac
    Campone, Mario
    [J]. EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2021, 17 (02) : 139 - 152
  • [9] Metformin (MET) for the prevention of Alpelisib (ALP)-related Hyperglycemia (HG) in PIK3CA-mutated, Hormone Receptor-Positive (HR[+]) HER2-Negative (HER2[-]) Advanced Breast Cancer (ABC): The METALLICA study
    Borrego, Manuel Ruiz
    Tolosa, Pablo
    Blanch, Salvador
    Fernandez, Adela
    Urriticoechea, Ander
    Blancas, Isabel
    Saura, Cristina
    Rojas, Beatriz
    Bermejo, Begona
    Ponce, Jose
    Gion, Maria
    Llabres, Elisenda
    Galve, Elena
    Cueva, Juan Fernando
    Lopez, Ana
    Alonso-Romero, Jose L.
    Gonzalez-Santiago, Santiago
    De Duenas, Eduardo Martinez
    Peralta, Fernando Gomez
    Ciruelos, Eva
    Perez-Garcia, Jose Manuel
    Llombart-Cussac, Antonio
    Cortes, Javier
    [J]. CANCER RESEARCH, 2023, 83 (05)
  • [10] Alpelisib: A Well-Tolerated Treatment Option for Patients with HR-Positive, HER2-Negative PIK3CA-Mutated Advanced Breast Cancer
    Diao, Fei-Yu
    [J]. GLOBAL MEDICAL GENETICS, 2022, 09 (01): : 1 - 3
12345